Literature DB >> 20028743

Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer.

Corinne Dahinden1, Barbara Ingold, Peter Wild, Gunther Boysen, Van-Duc Luu, Matteo Montani, Glen Kristiansen, Tullio Sulser, Peter Bühlmann, Holger Moch, Peter Schraml.   

Abstract

PURPOSE: Tumor stage and nuclear grade are the most important prognostic parameters of clear cell renal cell carcinoma (ccRCC). The progression risk of ccRCC remains difficult to predict particularly for tumors with organ-confined stage and intermediate differentiation grade. Elucidating molecular pathways deregulated in ccRCC may point to novel prognostic parameters that facilitate planning of therapeutic approaches. EXPERIMENTAL
DESIGN: Using tissue microarrays, expression patterns of 15 different proteins were evaluated in over 800 ccRCC patients to analyze pathways reported to be physiologically controlled by the tumor suppressors von Hippel-Lindau protein and phosphatase and tensin homologue (PTEN). Tumor staging and grading were improved by performing variable selection using Cox regression and a recursive bootstrap elimination scheme.
RESULTS: Patients with pT2 and pT3 tumors that were p27 and CAIX positive had a better outcome than those with all remaining marker combinations. A prolonged survival among patients with intermediate grade (grade 2) correlated with both nuclear p27 and cytoplasmic PTEN expression, as well as with inactive, nonphosphorylated ribosomal protein S6. By applying graphical log-linear modeling for over 700 ccRCC for which the molecular parameters were available, only a weak conditional dependence existed between the expression of p27, PTEN, CAIX, and p-S6, suggesting that the dysregulation of several independent pathways are crucial for tumor progression.
CONCLUSIONS: The use of recursive bootstrap elimination, as well as graphical log-linear modeling for comprehensive tissue microarray (TMA) data analysis allows the unraveling of complex molecular contexts and may improve predictive evaluations for patients with advanced renal cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028743     DOI: 10.1158/1078-0432.CCR-09-0260

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

1.  A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Authors:  Natsuko Suwaki; Elsa Vanhecke; Katelyn M Atkins; Manuela Graf; Katherine Swabey; Paul Huang; Peter Schraml; Holger Moch; Amy Mulick Cassidy; Daniel Brewer; Bissan Al-Lazikani; Paul Workman; Johann De-Bono; Stan B Kaye; James Larkin; Martin E Gore; Charles L Sawyers; Peter Nelson; Tomasz M Beer; Hao Geng; Lina Gao; David Z Qian; Joshi J Alumkal; Gary Thomas; George V Thomas
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

Review 2.  Personalized cancer medicine and the future of pathology.

Authors:  H Moch; P R Blank; M Dietel; G Elmberger; K M Kerr; J Palacios; F Penault-Llorca; G Rossi; T D Szucs
Journal:  Virchows Arch       Date:  2011-12-06       Impact factor: 4.064

3.  [The WHO/ISUP grading system for renal carcinoma].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

4.  Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Authors:  Luciana Schultz; Alcides Chaux; Roula Albadine; Jessica Hicks; Jenny J Kim; Angelo M De Marzo; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

5.  Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma.

Authors:  Karl-Friedrich Deml; Hans-Ulrich Schildhaus; Eva Compérat; Adriana von Teichman; Martina Storz; Peter Schraml; Joseph V Bonventre; Falko Fend; Barbara Fleige; Andreas Nerlich; Helmut E Gabbert; Nikolaus GaBler; Rainer Grobholz; Seife Hailemariam; Raoul Hinze; Ruth Knüchel; Benoit Lhermitte; Gabriella Nesi; Thomas Rüdiger; Guido Sauter; Holger Moch
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

6.  Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.

Authors:  Gunther Boysen; Damaris Bausch-Fluck; Claudio R Thoma; Anna M Nowicka; Daniel P Stiehl; Igor Cima; Van-Duc Luu; Adriana von Teichman; Thomas Hermanns; Tullio Sulser; Barbara Ingold-Heppner; Niklaus Fankhauser; Roland H Wenger; Wilhelm Krek; Peter Schraml; Bernd Wollscheid; Holger Moch
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

Review 7.  [Renal cancer biomarkers. What is justified?].

Authors:  H Moch
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

8.  Relevance of periostin splice variants in renal cell carcinoma.

Authors:  Laura Morra; Markus Rechsteiner; Silvia Casagrande; Van Duc Luu; Roger Santimaria; Pierre A Diener; Tullio Sulser; Glen Kristiansen; Peter Schraml; Holger Moch; Alex Soltermann
Journal:  Am J Pathol       Date:  2011-07-18       Impact factor: 4.307

Review 9.  Basic research in kidney cancer.

Authors:  Egbert Oosterwijk; W Kimryn Rathmell; Kerstin Junker; A Rose Brannon; Frédéric Pouliot; David S Finley; Peter F A Mulders; Ziya Kirkali; Hirotsugo Uemura; Arie Belldegrun
Journal:  Eur Urol       Date:  2011-07-05       Impact factor: 20.096

Review 10.  Renal cell carcinoma: where will the state-of-the-art lead us?

Authors:  A Rose Brannon; W Kimryn Rathmell
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.